Between July 7, 2023, and June 30, 2024, Houston-based University of Texas MD Anderson had the lowest rate of Clostridioides difficile infections among cancer hospitals exempt from reporting to Medicare’s Inpatient Prospective Payment System.
Eleven PPS-exempt cancer hospitals are required to participate in the PPS-Exempt Cancer Hospital Quality Reporting Program, a specialized quality reporting program established in 2010 by the ACA.
Healthcare associated infections are measured by a standard infection ratio, which compares the observed number of infections to the number of predicted infections.
All 11 PPS-exempt cancer hospitals reported C. diff infection rates under the national C. diff infection rate.
Here are the C. diff infection rates of PPS-exempt cancer hospitals between July 7, 2023, and June 30, 2024, according to CMS data:
- University of Texas MD Anderson Cancer Center (Houston): 0.237
- University of Miami Sylvester Comprehensive Cancer Center: 0.38
- Moffitt Cancer Center (Tampa, Fla.): 0.382
- Memorial Sloan Kettering Cancer Center (New York City): 0.437
- The James Cancer Hospital and Solove Research Institute (Columbus, Ohio): 0.453
- Fox Chase Cancer Center (Philadelphia): 0.598
- Roswell Park Cancer Institute (Buffalo, N.Y.): 0.694
- Dana-Farber Cancer Institute (Boston): 0.711
- USC Kenneth Norris Jr. Cancer Hospital (Los Angeles): 0.796
- Fred Hutchinson Cancer Institute (Seattle): 0.874
- City of Hope (Duarte, Calif.): 0.877
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
